Journal Finder

Molecular Medicine is the international, peer-reviewed, biomedical journal published by the Feinstein Institute for Medical Research (New York). Molecular Medicine strives to understand normal body functioning and disease pathogenesis at the molecular level, which may allow researchers and physician-scientists to use that knowledge in the design of specific molecular tools for disease diagnosis, treatment, prognosis, and prevention. Manuscripts submitted to the journal should maintain this focus and describe the implications for human disease, at a level approachable by the broad readership of Molecular Medicine. The 2011 Journal Citation Report (JCR), showing impact factors calculated from citations of articles published in 2010 and 2009, lists Molecular Medicine with an impact factor of 3.757. JCR category rankings are as follows: Medicine, Research & Experimental 24/111, Cell Biology 72/180, Biochemistry & Molecular Biology 91/289. Molecular Medicine publishes work in the format of original research articles, review articles, editorials, commentaries and letters to the editor covering emerging concepts in the interdisciplinary field of molecular medicine.Molecular Medicine places high priority on rapid publication. All content is published free online, ahead of print, within an average of 8 days after acceptance on our Web site www.molmed.org. Following acceptance, papers are posted rapidly to PubMed, with an e-publication ahead of print citation. Molecular Medicine is an open access journal and does not embargo content.

* Biological Abstracts® (Thomson ISI) * BIOSIS Previews® (Thomson ISI) * Chemical Abstracts Service (CAS) * EMBASE (Elsevier) * Google Scholar * Index Copernicus (IC) * Index Medicus/MEDLINE/PubMed (NLM) * Journal Citation Reports (JCR) Science Edition (Thomson ISI) * Science Citation Index Expanded® (Thomson ISI) * Scopus (Elsevier).

Molecular Pain is ready to receive manuscripts on all aspects of pain research at the cellular, subcellular and molecular levels. Molecular Pain is sponsored by the University of Cincinnati College of Medicine.

Monthly issues present original applications of biochemistry, biophysics, genetics, and molecular biology juxtaposed with innovative pharmacologic research to elucidate basic problems in pharmacology and toxicology, including areas such as molecular mechanisms involved in drug receptor-effective coupling, xenobiotic metabolism, and antibiotic and anticancer drug action.Molecular Pharmacology is archived in CLOCKSS.

Molecular Therapy is the leading journal for research in the areas of gene transfer, vector development and design, stem cell manipulation, development of gene-, peptide- and protein-, oligonucleotide- and cell-based therapeutics to correct genetic and acquired diseases, vaccine development, pre-clinical target validation, safety/efficacy studies, and clinical trials. Available in print and online, Molecular Therapy is dedicated to promoting the sciences in genetics, medicine and biotechnology. Publishing important peer-reviewed research and cutting-edge reviews and commentaries, the journal continues to attract the best material in the field. Molecular Therapy's 2009 impact factor is 6.239*.

methods, technology development, molecular therapy, gene therapy

Molecular Therapy — Nucleic Acids publishes research targeted to the advances in nucleic acid-based therapeutics to treat and/or correct genetic and acquired disease. Subject areas include: development of therapeutics based on nucleic acids and their derivatives, vector development and design for the delivery of RNA-based therapeutics, and applications of gene-modifying agents.

Our aim is to encourage chemists to publish as much as possible their experimental detail, particularly synthetic procedures and characterization information. There is no restriction on the length of the experimental section. In addition, availability of compound samples is published and considered as important information. Authors are encouraged to register or deposit their chemical samples through the non-profit international organization Molecular Diversity Preservation International (MDPI).

NMR in Biomedicine is a journal devoted to the publication of original full-length papers, rapid communications and review articles describing the development of magnetic resonance spectroscopy or imaging methods or their use to investigate physiological, biochemical, biophysical or medical problems. Topics for submitted papers should be in one of the following general categories: (a) development of methods and instrumentation for MR of biological systems; (b) studies of normal or diseased organs, tissues or cells; (c) diagnosis or treatment of disease. Reports may cover work on patients or healthy human subjects, in vivo animal experiments, studies of isolated organs or cultured cells, analysis of tissue extracts, NMR theory, experimental techniques, or instrumentation. The Journal will not accept any papers that deal solely with body fluids. NMR in Biomedicine will accept for review manuscripts that focus on the use of MRI contrast agents in practical applications, but not those that are primarily concerned with the development, synthesis or ex vivo testing of contrast agents.

The mission of Nanomedicine: Nanotechnology, Biology, and Medicine (Nanomedicine: NBM) is to promote the emerging interdisciplinary field of nanomedicine.Nanomedicine: NBM is an international, peer-reviewed journal presenting novel, significant, and interdisciplinary theoretical and experimental results related to nanoscience and nanotechnology in the life sciences. Content includes basic, translational, and clinical research addressing diagnosis, treatment, monitoring, prediction, and prevention of diseases. In addition to bimonthly issues, the journal website (http://www.nanomedjournal.com) also presents important nanomedicine-related information, such as future meetings, meeting summaries, funding opportunities, societal subjects, public health, and ethical issues of nanomedicine.The potential scope of nanomedicine is broad, and we expect it to eventually involve all aspects of medicine. Sub-categories include synthesis, bioavailability, and biodistribution of nanomedicines; delivery, pharmacodynamics, and pharmacokinetics of nanomedicines; imaging; diagnostics; improved therapeutics; innovative biomaterials; interactions of nanomaterials with cells, tissues, and living organisms; regenerative medicine; public health; toxicology; point of care monitoring; nutrition; nanomedical devices; prosthetics; biomimetics; and bioinformatics.Article formats include Communications, Original Articles, Reviews, Perspectives, Technical and Commercialization Notes, and Letters to the Editor. We invite authors to submit original manuscripts in these categories. The journal website (http://www.nanomedjournal.com) also presents important nanomedicine-related information, such as future meetings, meeting summaries, funding opportunities, societal subjects, public health, and ethical issues of nanomedicine.

NeuroMolecular Medicine presents cutting-edge research articles and critical reviews on the molecular and biochemical basis of neurological disorders. Coverage ranges from genetic analyses of human populations to animal and cell culture models of neurological disorders, and includes findings concerning the identification of genetic aberrancies and their pathogenic mechanisms at the molecular and cellular levels. Coverage includes experimental analyses of molecular cascades involved in the development and adult plasticity of the nervous system, in neurological dysfunction, and in neuronal degeneration and repair. NeuroMolecular Medicine encompasses basic research in molecular genetics, signal transduction, plasticity, and cell death. The journal gives special attention to synthetic research and reviews that aim to bridge genetic aberrancies with cellular and molecular mechanisms of neurological pathogenesis.

NJC (New Journal of Chemistry) is a broad-based primary journal encompassing all branches of chemistry and its sub-disciplines. It publishes high-quality work that opens new directions in chemistry or in other scientific disciplines. Research must demonstrate that it will have an impact on areas of research other than that of the reported work.

Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of targeted radiotracers. The importance of the target to a key disease should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized.These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field.Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed. Supplemental information on the Aims and Scope can be found in the Jan issue of the Journal and at www.nucmedbio.com.

Nucleosides, Nucleotides & Nucleic Acids publishes research articles, short notices, and concise, critical reviews of related topics that focus on the chemistry and biology of nucleosides, nucleotides, and nucleic acids. Complete with experimental details, this all-inclusive journal emphasizes the synthesis, biological activities, new and improved synthetic methods, and significant observations related to new compounds. Publication office: Taylor & Francis, Inc., 325 Chestnut Street, Suite 800, Philadelphia, PA 19106.

Access the Genetic Engineering & Biotechnology News (GEN)podcast interview with Eugene Kolker, PhD, Seattle Children's Hospital, Seattle Children's Research Institute, and Editor-in-Chief, OMICS and Vural Ozdemir, MD, PhD, University of Montreal here:THE EMERGING FIELD OF NUTRIGENOMICSOMICS: A Journal of Integrative Biology is the only peer-reviewed journal to span all the OMICS-es to date, including: Genomics (the quantitative study of genes, regulatory and non-coding sequences) Transcriptomics (RNA and gene expression) Proteomics (protein expression) Metabolomics (metabolites and metabolic networks)Additionally, the Journal explores advances in the era of post-genomic biology and medicine, including: Pharmacogenomics (the quantitative study of how genetics affects hosts' responses to drugs) Physiomics (physiological dynamics and functions of whole organisms)The Journal covers the integration of many areas of biology and reports on the latest omics research, developments, and discoveries such as: Physical mapping and sequencing Gene and protein expression Peptide identifications Bacterial coding capabilities Developments in plant research Spectral analysis methods.

Personalized Medicine is a peer-reviewed journal presenting reviews and reports by scientists and decision-makers most closely involved in this rapidly developing area. Personalized Medicine aims at being an essential resource for keeping abreast of the latest developments in all areas of this exciting new field, and focuses on those aspects of most direct relevance to the pharmaceutical industry and wider clinical community.